<table>
<thead>
<tr>
<th>Number of Cases</th>
<th>Percentage</th>
<th>Incidence rates per million person-years</th>
<th>MV</th>
<th>DCO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age group</td>
<td>0-14 All Group</td>
<td>0-19 All Group</td>
<td>0-14 Age-specific</td>
<td>0-19 Age-specific</td>
</tr>
<tr>
<td>5-9</td>
<td>20.1</td>
<td>20.1</td>
<td>18.9</td>
<td>20.1</td>
</tr>
<tr>
<td>10-14</td>
<td>20.1</td>
<td>20.1</td>
<td>18.9</td>
<td>20.1</td>
</tr>
<tr>
<td>15-19</td>
<td>20.1</td>
<td>20.1</td>
<td>18.9</td>
<td>20.1</td>
</tr>
<tr>
<td>19-29</td>
<td>20.1</td>
<td>20.1</td>
<td>18.9</td>
<td>20.1</td>
</tr>
<tr>
<td>30-44</td>
<td>20.1</td>
<td>20.1</td>
<td>18.9</td>
<td>20.1</td>
</tr>
<tr>
<td>45-64</td>
<td>20.1</td>
<td>20.1</td>
<td>18.9</td>
<td>20.1</td>
</tr>
<tr>
<td>65+</td>
<td>20.1</td>
<td>20.1</td>
<td>18.9</td>
<td>20.1</td>
</tr>
<tr>
<td>Total</td>
<td>20.1</td>
<td>20.1</td>
<td>18.9</td>
<td>20.1</td>
</tr>
</tbody>
</table>

Please consult the quality indicators for this registry

International Incidence of Childhood Cancer Volume III http://icc.iarc.fr/results
<table>
<thead>
<tr>
<th></th>
<th>Number of cases in age groups</th>
<th>Number of cases in age groups</th>
<th>ASR per million</th>
<th>M/F ratio</th>
<th>Number of cases in age groups</th>
<th>Number of cases in age groups</th>
<th>ASR per million</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0-19</td>
<td>0-19</td>
<td>0-19</td>
<td>0-19</td>
<td>0-19</td>
<td>0-19</td>
<td>0-19</td>
</tr>
<tr>
<td></td>
<td>0-14</td>
<td>15-19</td>
<td>0-14</td>
<td>15-19</td>
<td>0-14</td>
<td>15-19</td>
<td>0-14</td>
</tr>
<tr>
<td><strong>LEUKAEMIA</strong></td>
<td><strong>LEUKAEMIA</strong></td>
<td><strong>LEUKAEMIA</strong></td>
<td><strong>LEUKAEMIA</strong></td>
<td><strong>LEUKAEMIA</strong></td>
<td><strong>LEUKAEMIA</strong></td>
<td><strong>LEUKAEMIA</strong></td>
<td><strong>LEUKAEMIA</strong></td>
</tr>
<tr>
<td>a. Lymphoid</td>
<td>3 17 12</td>
<td>4 6</td>
<td>36 42</td>
<td>45 43</td>
<td>39 1.4</td>
<td>1.6</td>
<td>1.6</td>
</tr>
<tr>
<td>b. Acute myeloid</td>
<td>2 3 2 5 2</td>
<td>12 14 13 7.6</td>
<td>4.2 8.0</td>
<td>1.0</td>
<td>2.0</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>c. CMD</td>
<td>0 0 0 1 3</td>
<td>1 4</td>
<td>1.0</td>
<td>3.1</td>
<td>1.0</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>d. MDS &amp; OTHER</td>
<td>0 1 0 0 1</td>
<td>1 1 1 1.0</td>
<td>0.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>e. unspecified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>LYMPHOID &amp; RELATED</strong></td>
<td><strong>LYMPHOID &amp; RELATED</strong></td>
<td><strong>LYMPHOID &amp; RELATED</strong></td>
<td><strong>LYMPHOID &amp; RELATED</strong></td>
<td><strong>LYMPHOID &amp; RELATED</strong></td>
<td><strong>LYMPHOID &amp; RELATED</strong></td>
<td><strong>LYMPHOID &amp; RELATED</strong></td>
<td><strong>LYMPHOID &amp; RELATED</strong></td>
</tr>
<tr>
<td>a. Hodgkin</td>
<td>0 1 1 2 6</td>
<td>4 10</td>
<td>4.6 8.2</td>
<td>1.4</td>
<td>1.4</td>
<td>1.4</td>
<td>1.4</td>
</tr>
<tr>
<td>b. Non-Hodgkin except BL</td>
<td>0 2 1 5 4</td>
<td>8 12</td>
<td>10.1 10.1</td>
<td>0.9</td>
<td>0.9</td>
<td>0.9</td>
<td>0.9</td>
</tr>
<tr>
<td>c. Burkitt (BL)</td>
<td>0 3 1 1 0</td>
<td>5 5</td>
<td>6.3 4.9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>d. Lymphoreticular</td>
<td>0 0 1 2 0</td>
<td>3 3</td>
<td>3.3 2.5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>e. unspecified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>NEUROBLASTOMA</strong></td>
<td><strong>NEUROBLASTOMA</strong></td>
<td><strong>NEUROBLASTOMA</strong></td>
<td><strong>NEUROBLASTOMA</strong></td>
<td><strong>NEUROBLASTOMA</strong></td>
<td><strong>NEUROBLASTOMA</strong></td>
<td><strong>NEUROBLASTOMA</strong></td>
<td><strong>NEUROBLASTOMA</strong></td>
</tr>
<tr>
<td>a. Ganglioneuroblastoma</td>
<td>2 6 1 0</td>
<td>9 9</td>
<td>12.0 9.3</td>
<td>0.9</td>
<td>0.9</td>
<td>0.9</td>
<td>0.9</td>
</tr>
<tr>
<td>b. Peripheral neural</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>RETILOCNESTOMA</strong></td>
<td><strong>RETILOCNESTOMA</strong></td>
<td><strong>RETILOCNESTOMA</strong></td>
<td><strong>RETILOCNESTOMA</strong></td>
<td><strong>RETILOCNESTOMA</strong></td>
<td><strong>RETILOCNESTOMA</strong></td>
<td><strong>RETILOCNESTOMA</strong></td>
<td><strong>RETILOCNESTOMA</strong></td>
</tr>
<tr>
<td>a. Nephroblastoma</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>b. Renal carcinoma</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>c. unspecified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>d. unspecified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>HEPATOCARCINOMA</strong></td>
<td><strong>HEPATOCARCINOMA</strong></td>
<td><strong>HEPATOCARCINOMA</strong></td>
<td><strong>HEPATOCARCINOMA</strong></td>
<td><strong>HEPATOCARCINOMA</strong></td>
<td><strong>HEPATOCARCINOMA</strong></td>
<td><strong>HEPATOCARCINOMA</strong></td>
<td><strong>HEPATOCARCINOMA</strong></td>
</tr>
<tr>
<td>a. Hepatoblastoma</td>
<td>1 3 0 0 0</td>
<td>4 4</td>
<td>5.4 4.2</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>b. Hepatic carcinoma</td>
<td>0 0 0 2 2</td>
<td>2 2</td>
<td>2.1 1.6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>c. unspecified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>d. unspecified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>BONE TUMOURS</strong></td>
<td><strong>BONE TUMOURS</strong></td>
<td><strong>BONE TUMOURS</strong></td>
<td><strong>BONE TUMOURS</strong></td>
<td><strong>BONE TUMOURS</strong></td>
<td><strong>BONE TUMOURS</strong></td>
<td><strong>BONE TUMOURS</strong></td>
<td><strong>BONE TUMOURS</strong></td>
</tr>
<tr>
<td>a. Osteosarcoma</td>
<td>0 0 0 3 3</td>
<td>4 3</td>
<td>3.1 3.2</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>b. Chondrosarcoma</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>c. Ewing &amp; related</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>d. Other specified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>e. unspecified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>SOFT TISSUE SARCOMA</strong></td>
<td><strong>SOFT TISSUE SARCOMA</strong></td>
<td><strong>SOFT TISSUE SARCOMA</strong></td>
<td><strong>SOFT TISSUE SARCOMA</strong></td>
<td><strong>SOFT TISSUE SARCOMA</strong></td>
<td><strong>SOFT TISSUE SARCOMA</strong></td>
<td><strong>SOFT TISSUE SARCOMA</strong></td>
<td><strong>SOFT TISSUE SARCOMA</strong></td>
</tr>
<tr>
<td>a. Rhabdomyosarcoma</td>
<td>0 4 1 0 1</td>
<td>5 6</td>
<td>6.6 5.9</td>
<td>2.5</td>
<td>2.0</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>b. Fibrosarcoma</td>
<td>1 0 0 0 1</td>
<td>1 1</td>
<td>1.3</td>
<td>1.3</td>
<td>1.3</td>
<td>1.3</td>
<td>1.3</td>
</tr>
<tr>
<td>c. Kaposi sarcoma</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>d. Other specified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>e. unspecified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>GERM CELL TUMOURS</strong></td>
<td><strong>GERM CELL TUMOURS</strong></td>
<td><strong>GERM CELL TUMOURS</strong></td>
<td><strong>GERM CELL TUMOURS</strong></td>
<td><strong>GERM CELL TUMOURS</strong></td>
<td><strong>GERM CELL TUMOURS</strong></td>
<td><strong>GERM CELL TUMOURS</strong></td>
<td><strong>GERM CELL TUMOURS</strong></td>
</tr>
<tr>
<td>a. CNS germ cell</td>
<td>0 2 1 1</td>
<td>3 4</td>
<td>4.7 6.1</td>
<td>0.4</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>b. Other extra gonadal</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>c. Gonadal germ cell</td>
<td>0 1 0 0 2</td>
<td>1 3</td>
<td>1.3 2.6</td>
<td>0.3</td>
<td>0.3</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>d. Gonadal carcinoma</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>e. unspecified gonadal</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>TUMOURS OF INCERTAIGINETY</strong></td>
<td><strong>TUMOURS OF INCERTAIGINETY</strong></td>
<td><strong>TUMOURS OF INCERTAIGINETY</strong></td>
<td><strong>TUMOURS OF INCERTAIGINETY</strong></td>
<td><strong>TUMOURS OF INCERTAIGINETY</strong></td>
<td><strong>TUMOURS OF INCERTAIGINETY</strong></td>
<td><strong>TUMOURS OF INCERTAIGINETY</strong></td>
<td><strong>TUMOURS OF INCERTAIGINETY</strong></td>
</tr>
<tr>
<td>a. Adrenocortical</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>b. Thyroid</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>c. Nasopharyngeal</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>d. Melanoma</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>e. Skin carcinoma</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>f. Other &amp; unspecified</td>
<td>0 0 0 0 0</td>
<td>0 0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>TOTAL</strong></td>
<td><strong>TOTAL</strong></td>
<td><strong>TOTAL</strong></td>
<td><strong>TOTAL</strong></td>
<td><strong>TOTAL</strong></td>
<td><strong>TOTAL</strong></td>
<td><strong>TOTAL</strong></td>
</tr>
<tr>
<td></td>
<td>9 52 33 32 43</td>
<td>126 169</td>
<td>154.7 152.8</td>
<td>1.1 1.0</td>
<td>1.1 1.0</td>
<td>1.1 1.0</td>
<td>1.1 1.0</td>
</tr>
</tbody>
</table>

Please consult the quality indicators for this registry.

International Incidence of Childhood Cancer Volume III [http://icc.iarc.fr/results]
<table>
<thead>
<tr>
<th>Age group</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>58 392</td>
<td>56 221</td>
</tr>
<tr>
<td>1-4</td>
<td>229 105</td>
<td>222 697</td>
</tr>
<tr>
<td>5-9</td>
<td>271 519</td>
<td>264 248</td>
</tr>
<tr>
<td>10-14</td>
<td>278 700</td>
<td>272 413</td>
</tr>
<tr>
<td>15-19</td>
<td>293 932</td>
<td>285 900</td>
</tr>
<tr>
<td>Total 0-14</td>
<td>837 716</td>
<td>815 579</td>
</tr>
<tr>
<td>Total 0-19</td>
<td>1 131 648</td>
<td>1 101 479</td>
</tr>
<tr>
<td>Average annual population 0-14</td>
<td>41 886</td>
<td>40 779</td>
</tr>
<tr>
<td>Average annual population 0-19</td>
<td>56 582</td>
<td>55 074</td>
</tr>
</tbody>
</table>

Please consult the quality indicators for this registry.

International Incidence of Childhood Cancer Volume III [http://iicc.iarc.fr/results]